Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533471 | 0.91 | CA1 (0.50) | DNM1CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL10856379 | 0.88 | DNM1 (0.48) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL60002 | 0.87 | DNM1 (0.53) | DNM1KDM4EHTTPOLBMEN1 | |
| SCHEMBL8396016 | 0.86 | EPHX1 (0.54) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL13670125 | 0.85 | EPHX1 (0.52) | DNM1KDM4EMEN1KMT2AEPHX1 | |
| Water SCHEMBL29264273 | 0.85 | DNM1 (0.51) | DNM1KDM4EHTTPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL15878572 | 0.85 | DNM1 (0.51) | DNM1KDM4EHTTPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL218974 | 0.85 | DNM1 (0.51) | DNM1KDM4EHTTPOLBMEN1 | |
| Iodomethane SCHEMBL4824562 | 0.84 | DNM1 (0.50) | DNM1KDM4EHTTPOLBMEN1 | |
| SCHEMBL23834129 | 0.81 | EPHX2 (0.40) | DNM1KDM4EHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218722-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3860561-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-2788316-B1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9687448-B2 | Nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2575764-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| CN-105949421-A | Temperature-sensitive catalyst used for solvent-free polyurethane synthesis, and preparation method thereof | 中国科学院福建物质结构研究所 | 2016-09-21 | — | — | CN | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| US-20070112044-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112044-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
| US-4097600-A | ANTICARIES AGENTS | COLGATE PALMOLIVE COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-4082756-A | QUATERNARY QUINUCLIDINIUM CARBAMATES AND THIOCARBAMATES | COLGATE-PALMOLIVE COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4038303-A | QUATERNARY AMMONIUM CARBAMIDE COMPOUNDS | COLGATE-PALMOLIVE COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4007281-A | Pharmaceutical compositions containing quaternary ammonium compounds | COLGATE-PALMOLIVE COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-3956479-A | ANTICARIES AGENTS, FUNGICIDES, BACTERICIDES, DENTIFRICES, MOUTHWASHES, CARBAMATES, THIOCARBAMATES | COLGATE-PALMOLIVE COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | DNM1 442/4885CA1 3362/4885CA2 3065/4885 |
| US-20070112044-A1 | Thiadiazoline derivative | TLK2, TLK1, BRWD1 | DNM1 3646/4885CA1 4804/4885CA2 4492/4885 |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | DNM1 1159/4885CA1 2542/4885CA2 1930/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | DNM1 984/4885CA1 4797/4885CA2 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.